Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MK3207-003 | |||
| 2007_599 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A study to assess safety and PK of an investigational drug in migraine patients during and between migraine attacks.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | MK3207 Orally administered to patients with water. During each period (with and without acute migraine). |
|
| 2 | Placebo Comparator | MK3207 placebo as tablets will be Orally administered to patients with water. During each period (with and without acute migraine). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MK3207 | Drug | M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety in migraine patients | 12 Weeks |
| Measure | Description | Time Frame |
|---|---|---|
| PK in migraine patients | 12 Weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Merck Sharp & Dohme LLC | Study Director |
Not provided
| ID | Term |
|---|---|
| D008881 | Migraine Disorders |
| ID | Term |
|---|---|
| D051270 | Headache Disorders, Primary |
| D020773 | Headache Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C548781 | 2-(8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro(4.5)dec-9-yl)-N-(2'-oxo-1,1',2',3-tetrahydrospiro(indene-2,3'-pyrrolo(2,3-b)pyridin)-5-yl)acetamide |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Comparator: Placebo (unspecified) | Drug | M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets). |
|
| D009422 | Nervous System Diseases |